Krazati (adagrasib) followed sotorasib into the KRAS G12C space, arriving as the second approved inhibitor of a target once considered undruggable.
Adagrasib binds the mutant protein irreversibly and covalently, and its longer half-life and central nervous system penetration distinguish it pharmacologically from sotorasib. The twice-daily tablet treats adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy.
Krazati remains under an ongoing accelerated approval and has since added a colorectal cancer indication in combination with cetuximab. Its brain metastasis activity is the main clinical differentiator, and the asset anchored Bristol Myers Squibb’s acquisition of Mirati.
